Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06261840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint revised
    • Secondary endpoints expanded, about 65 words
    • Collaborators revised (3)
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Start date changed from estimate of Jul 1, 2024 to May 6, 2025
    • Study sites: 0 to 4
    • Eligibility criteria expanded, about 53 words
    • Collaborators: 2 to 3
    • Study description expanded, about 1 word
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.
Trial Details
NCT Number NCT06261840
Lead Sponsor Tulane University
Collaborators: University of Alabama at Birmingham, Louisiana State University Health Sciences Center in New Orleans, Healthcare Clinical Data
Conditions
(from sponsor)		 Trichomonas Vaginitis, Bacterial Vaginitis
Related terms Trichomonas Vaginitis, Vaginosis, Bacterial
Enrollment 1,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov